{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:36:34Z","timestamp":1784039794734,"version":"3.55.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00277-017-3191-7","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T05:46:18Z","timestamp":1514353578000},"page":"387-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?"],"prefix":"10.1007","volume":"97","author":[{"given":"Xavier","family":"Leleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Flament","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Allcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"issue":"1","key":"3191_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw 7(1):99\u2013108. https:\/\/doi.org\/10.6004\/jnccn.2009.0009","journal-title":"J Natl Compr Cancer Netw"},{"issue":"Suppl 4","key":"3191_CR2","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1086\/427329","volume":"40","author":"C Viscoli","year":"2005","unstructured":"Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):S240\u2013S245. https:\/\/doi.org\/10.1086\/427329","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3191_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1(1):23\u201335. https:\/\/doi.org\/10.3816\/SCT.2003.n.002","journal-title":"Support Cancer Ther"},{"issue":"8","key":"3191_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49(8):1211\u20131225. https:\/\/doi.org\/10.1086\/605664","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3191_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.14670\/HH-20.1227","volume":"20","author":"HR Raeve De","year":"2005","unstructured":"De Raeve HR, Vanderkerken K (2005) The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 20(4):1227\u20131250. 10.14670\/HH-20.1227","journal-title":"Histol Histopathol"},{"issue":"5","key":"3191_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138(5):563\u2013579. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06705.x","journal-title":"Br J Haematol"},{"issue":"1","key":"3191_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"1","key":"3191_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","volume":"12","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Blade J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5\u201311. https:\/\/doi.org\/10.1016\/j.clml.2011.11.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004386.pub3","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386. https:\/\/doi.org\/10.1002\/14651858.CD004386.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3191_CR10","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3191_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100(6):624\u2013628. https:\/\/doi.org\/10.1016\/S0002-9343(95)00043-7","journal-title":"Am J Med"},{"issue":"1","key":"3191_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-Oncology Task Force of British Committee for Standards in Haematology, U. K. Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154(1):32\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08573.x","journal-title":"Br J Haematol"},{"issue":"3","key":"3191_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1634\/theoncologist.2014-0073","volume":"20","author":"Z Hanaizi","year":"2015","unstructured":"Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F (2015) The European Medicines Agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 20(3):329\u2013334. https:\/\/doi.org\/10.1634\/theoncologist.2014-0073","journal-title":"Oncologist"},{"issue":"23","key":"3191_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"B Durie","year":"2015","unstructured":"Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2015) Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (PTS) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 126(23):25","journal-title":"Blood"},{"issue":"3","key":"3191_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/10428194.2012.719614","volume":"54","author":"VH Jimenez-Zepeda","year":"2013","unstructured":"Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V (2013) Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 54(3):555\u2013560. https:\/\/doi.org\/10.3109\/10428194.2012.719614","journal-title":"Leuk Lymphoma"},{"key":"3191_CR16","doi-asserted-by":"crossref","unstructured":"Garcia-Sanchez R, Gonzalez-Fernandez A, Garcia-Fortes M, Rivas-Luque M, Fernandez-Fernandez A, Cabrera Ruiz F, Campos-Garrigues A, Caparros-Miranda I, Queipo De Llano-Temboury MP, Rosell-Mas A, Ruiz-Arredondo JJ (2015) Frontline treatment scheme VTD (bortezomib\/thalidomide\/dexamethasone) in patients with multiple myeloma transplant candidates at our center. Clin Lymphoma Myeloma Leuk 15(Suppl 3):e168\u2013e169","DOI":"10.1016\/j.clml.2015.07.388"},{"key":"3191_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2015-03-635805","volume":"126","author":"P Moreau","year":"2015","unstructured":"Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangha O, Glaisner S, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Lenain P, Planche L, Biron L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M (2015) Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Blood 126:393","journal-title":"Blood"},{"key":"3191_CR18","doi-asserted-by":"crossref","unstructured":"Niesvizky R, Flinn IW, Rifkin RM, Gabrail NY, Charu V, Clowney B, Essell J, Gaffar YA, Warr TA, Neuwirth R, Corzo D, Reeves JA (2010) Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Blood 116:619","DOI":"10.1182\/blood.V116.21.619.619"},{"issue":"2","key":"3191_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12185-014-1611-1","volume":"100","author":"S Takashima","year":"2014","unstructured":"Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K (2014) Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol 100(2):159\u2013164. https:\/\/doi.org\/10.1007\/s12185-014-1611-1","journal-title":"Int J Hematol"},{"key":"3191_CR20","doi-asserted-by":"publisher","first-page":"927105","DOI":"10.1155\/2015\/927105","volume":"2015","author":"S Wu","year":"2015","unstructured":"Wu S, Zheng C, Chen S, Cai X, Shi Y, Lin B, Chen Y (2015) Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients. Biomed Res Int 2015:927105. https:\/\/doi.org\/10.1155\/2015\/927105","journal-title":"Biomed Res Int"},{"issue":"8","key":"3191_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29(8):1721\u20131729. https:\/\/doi.org\/10.1038\/leu.2015.80","journal-title":"Leukemia"},{"issue":"6","key":"3191_CR22","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","volume":"19","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19(6):1160\u20131165. https:\/\/doi.org\/10.1093\/annonc\/mdn018","journal-title":"Ann Oncol"},{"key":"3191_CR23","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/j.clml.2015.07.552","volume":"15","author":"Y Kusano","year":"2015","unstructured":"Kusano Y, Terui Y, Hatake K (2015) CyBorD demonstrated its superiority to bortezomib plus dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 15:e262\u2013e263. https:\/\/doi.org\/10.1016\/j.clml.2015.07.552","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18_suppl","key":"3191_CR24","doi-asserted-by":"crossref","first-page":"LBA8025","DOI":"10.1200\/jco.2007.25.18_suppl.lba8025","volume":"25","author":"SV Rajkumar","year":"2007","unstructured":"Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P (2007) Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 25(18_suppl):LBA8025","journal-title":"J Clin Oncol"},{"key":"3191_CR25","first-page":"S103","volume":"96","author":"M Beksac","year":"2011","unstructured":"Beksac M, Ozdemir E, Yagci M, Buyukkececi F, Cagirgan S, Ozdogu H, Kalayoglu Besisik S, Demirkan F, Uskent N, Kaygusuz I, Firat Tuglular T, Goker H, Ozcan MA, Cetiner M, Akyol Erikci A, Turgut B (2011) Clinical experience with lenalidomide and dexamethasone (Len + Dex) for the treatment of patients with relapsed\/refractory multiple myeloma (MM): safety and efficacy data from the Turkish compassionate use program (cup). Haematologica 96:S103\u2013S104","journal-title":"Haematologica"},{"key":"3191_CR26","first-page":"104","volume":"98","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos M, Petrucci M, Foa R, Catalano J, Kropff M, Yu Z, Herbein L, Grote L, Jacques C, Palumbo A (2013) Therapy following relapse on melphalan-prednisonelenalidomide (LEN) followed by Len maintenance in elderly newly diagnosed multiple myeloma patients: efficacy and safety of second line LEN in MM-015. Haematologica 98:104\u2013105","journal-title":"Haematologica"},{"key":"3191_CR27","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Migkou M, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Christoulas D, Terpos E, Kastritis E (2012) Lenalidomide with low or intermediate dose dexamethasone in patients with relapsed or refractory myeloma. Blood 120:4028","DOI":"10.1182\/blood.V120.21.4028.4028"},{"key":"3191_CR28","first-page":"220","volume":"99","author":"T Facon","year":"2014","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Hulin C, Cavo M, Pinto A, Weisel KC, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, Qiu L, White D, Binder D, Anderson KC, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques CJ, Ervin- Haynes A, Benboubker L (2014) Lenalidomide+low-dose dexamethasone (RD) vs. melphalan-prednisone-thalidomide (MPT) in newly diagnosed multiple myeloma (NDMM) patients (PTS): the FIRST trial. Haematologica 99:220\u2013221","journal-title":"Haematologica"},{"issue":"23","key":"3191_CR29","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V126.23.3257.3257","volume":"126","author":"L Family","year":"2015","unstructured":"Family L, Yang SJ, Klippel Z, Li Y, Page JH, Rodriguez R, Chao C (2015) Risk of febrile neutropenia (FN) in select myelosuppressive chemotherapy regimens. Blood 126(23):3257","journal-title":"Blood"},{"key":"3191_CR30","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.clml.2015.07.611","volume":"15","author":"T Firatli Tuglular","year":"2015","unstructured":"Firatli Tuglular T, Pehlivan M, Is H, Ayyildiz MO, Saydam G, Sonmez M, Kalayotlu Besisik S, Ozgur G, Gurkan E, Kaynar L, Ali R, Ozet G, Demirkan F, Ongoren S, Ozdotu H, Gunduz E, Naci Tiftik E, Salim O, Turgut M, Hacihanefiotlu A, Barbaros Ure U, Ozdemir E, Altuntas F, Simsek D, Ulu N, Beksac M (2015) Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed\/refractory multiple myeloma in Turkey. Clin Lymphoma Myeloma Leuk 15:e301\u2013e302. https:\/\/doi.org\/10.1016\/j.clml.2015.07.611","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR31","first-page":"614","volume":"98","author":"T Firatli Tuglular","year":"2013","unstructured":"Firatli Tuglular T, Noyan-Atalay F, Eser A, Toptas T, Pepedil F, Kaygusuz-Atagunduz I, Adiguzel C (2013) Lenalidomide in combination with low-dose dexamethasone in relapse\/refractory multiple myeloma: a retrospective study. Haematologica 98:614\u2013615","journal-title":"Haematologica"},{"issue":"20","key":"3191_CR32","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1002\/cncr.28274","volume":"119","author":"G Fouquet","year":"2013","unstructured":"Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X (2013) Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 119(20):3680\u20133686. https:\/\/doi.org\/10.1002\/cncr.28274","journal-title":"Cancer"},{"key":"3191_CR33","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.clml.2012.09.003","volume":"13","author":"C Geraldes","year":"2013","unstructured":"Geraldes C, Pereira M, Magalhaes E, Gomes M, Afonso R, Sousa I, Teixeira A (2013) Results from real life: lenalidomide & dexamethasone in relapsed or refractory multiple myeloma outside clinical trials. Clin Lymphoma Myeloma Leuk 13:S162\u2013S163","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.607","volume":"15","author":"SY Huang","year":"2015","unstructured":"Huang SY, Yu YB, Yeh SP, Chen TY, Kao WY, Chen CC, Wang MC, Lin HY, Lin SF, Lin TH, Hua Y, Puccio-Pick M, DeMarco D, Jacques C, Dunn P (2015) A non-interventional observational registry of patients (Pts) with relapsed\/refractory multiple myeloma (RRMM) treated with lenalidomide (LEN) and dexamethasone (DEX) in Taiwan. Clin Lymphoma Myeloma Leuk 15:e299. https:\/\/doi.org\/10.1016\/j.clml.2015.07.607","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR35","doi-asserted-by":"crossref","unstructured":"Mookerjee A, Gupta R, Sharma A, Saikia T, Kumar L (2011) Lenalidomide plus low-dose dexamethasone compared with thalidomide plus low-dose dexamethasone: a randomised phase III study. Blood 118(21)","DOI":"10.1182\/blood.V118.21.2932.2932"},{"issue":"23","key":"3191_CR36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V126.23.727.727","volume":"126","author":"P Moreau","year":"2015","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar SK, Touzeau C, Buadi F, Laubach JP, Lin J, Berg D, DiBacco A, Hui AM, Richardson PG (2015) Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRD), significantly extends progression-free survival (PFS) for patients (PTS) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 TOURMALINE-MM1 study (NCT01564537). Blood 126(23):727","journal-title":"Blood"},{"key":"3191_CR37","first-page":"291","volume":"37","author":"A Schwarzer","year":"2014","unstructured":"Schwarzer A, Fruhauf S, Konigsmann M, Schnell R, Reeb M, Heits F, Tirier C, Prange-Krex G, Knauf W, Bachinger A, Weiligmann C, Hoppe G, Glasmacher A, Schmidt B (2014) Treatment of relapsed\/refractory multiple myeloma patients with lenalidomide\/dexamethasone in routine clinical practice. Oncol Res Treatment 37:291","journal-title":"Oncol Res Treatment"},{"issue":"1","key":"3191_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4084\/mjhid.2013.037","volume":"5","author":"P Tosi","year":"2013","unstructured":"Tosi P, Gamberi B, Castagnari B, Molinari AL, Savini P, Ceccolini M, Tani M, Merli A, Imola M, Mianulli AM, Cellini C, Tomassetti S, Merli F, Fattori P, Zaccaria A (2013) Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. Mediterr J Hematol Infect Dis 5(1):1\u20135","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"26","key":"3191_CR39","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","volume":"116","author":"JA Zonder","year":"2010","unstructured":"Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore Jr DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116(26):5838\u20135841. https:\/\/doi.org\/10.1182\/blood-2010-08-303487","journal-title":"Blood"},{"issue":"9","key":"3191_CR40","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3109\/10428194.2012.662643","volume":"53","author":"A Alegre","year":"2012","unstructured":"Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B (2012) Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leukemia & Lymphoma 53(9):1714\u20131721. https:\/\/doi.org\/10.3109\/10428194.2012.662643","journal-title":"Leukemia & Lymphoma"},{"issue":"21","key":"3191_CR41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"issue":"8","key":"3191_CR42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24416","volume":"91","author":"X Leleu","year":"2016","unstructured":"Leleu X, Terpos E, Garc\u00eda Sanz R, Cooney J, O'Gorman P, Minarik J, Greil R, Williams C, Gray D, Szabo Z (2016) An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed\/refractory multiple myeloma (RR-MM). Am J Hematol 91(8):806\u2013811. https:\/\/doi.org\/10.1002\/ajh.24416","journal-title":"Am J Hematol"},{"issue":"7","key":"3191_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, KL W, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"3191_CR44","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, Miguel JFS, Ludwig H, Zojwalla N, Tonda ME, Xing B, Moreau P, Palumbo A (2014) Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients (Pts) with relapsed multiple myeloma: interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study. Blood 124(21)","DOI":"10.1182\/blood.V124.21.79.79"},{"issue":"2","key":"3191_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/10428194.2014.915544","volume":"56","author":"HL Sun","year":"2015","unstructured":"Sun HL, Atenafu EG, Yeboah E, Reece DE, Trudel S, Kukreti V, Masih-Khan E, Winter A, Chen C (2015) Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia and Lymphoma 56(2):407\u2013414. https:\/\/doi.org\/10.3109\/10428194.2014.915544","journal-title":"Leukemia and Lymphoma"},{"issue":"21","key":"3191_CR46","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133\u20132142. https:\/\/doi.org\/10.1056\/NEJMoa070596","journal-title":"N Engl J Med"},{"issue":"22","key":"3191_CR47","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azais I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol 27(22):3664\u20133670. https:\/\/doi.org\/10.1200\/JCO.2008.21.0948","journal-title":"J Clin Oncol"},{"issue":"2","key":"3191_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1365-2141.2011.08569.x","volume":"153","author":"PG Richardson","year":"2011","unstructured":"Richardson PG, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF (2011) Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol 153(2):212\u2013221. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08569.x","journal-title":"Br J Haematol"},{"issue":"19","key":"3191_CR49","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Yehuda DB, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759\u20131769. https:\/\/doi.org\/10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"issue":"10","key":"3191_CR50","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med"},{"issue":"7","key":"3191_CR51","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omede P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M (2014) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32(7):634\u2013640. https:\/\/doi.org\/10.1200\/JCO.2013.52.0023","journal-title":"J Clin Oncol"},{"key":"3191_CR52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","volume":"98","author":"F Gay","year":"2013","unstructured":"Gay F, Bringhen S, Offidani M, Liberati A, Cellini C, Magarotto V, Benevolo G, Aitoro G, Patriarca F, Omede P, Conticello C, Montefusco V, Rossi D, Palladino C, Pour L, Allegra A, Pietrantuono G, Falcone A, Rocci A, Zambello R, Ledda A, Gentili S, Musto P, Boccadoro M, Hajek R, Palumbo A (2013) Efficacy and safety of 3 lenalidomide-based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial. Haematologica 98:95\u201396","journal-title":"Haematologica"},{"issue":"23","key":"3191_CR53","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1182\/blood.V126.23.4225.4225","volume":"126","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Weisel KC, Ocio EM, Di Raimondo F, Hansson M, Simcock M, Miller N, Slaughter A, Peluso T, Sternas L, Zaki MH, Moreau P (2015) An updated analysis of the stratus trial (MM-010): safety and efficacy of pomalidomide plus low-dose dexamethasone (POM + LODEX) in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM). Blood 126(23):4225","journal-title":"Blood"},{"key":"3191_CR54","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/j.clml.2015.07.590","volume":"15","author":"N Maciocia","year":"2015","unstructured":"Maciocia N, Sharpley F, Belsham E, Renshaw H, Schey S, Cheesman S, Cerner A, Rismani A, D'Sa S, Streetly M, Reuben B, Jenner M, Ramasamy K, Yong K, Rabin N (2015) Outcome of pomalidomide therapy in relapsed\/refractory myeloma: a UK multi-centre experience. Clin Lymphoma Myeloma Leuk 15:e288\u2013e289. https:\/\/doi.org\/10.1016\/j.clml.2015.07.590","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR55","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/j.clml.2015.07.612","volume":"15","author":"O Miles","year":"2015","unstructured":"Miles O, Wells M (2015) Efficacy of pomalidomide after progression following lenalidomide and bortezomib\u2014a multicenter retrospective study. Clin Lymphoma Myeloma Leuk 15:e302. https:\/\/doi.org\/10.1016\/j.clml.2015.07.612","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3191_CR56","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055\u20131066. https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"issue":"8","key":"3191_CR57","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"G Cook","year":"2014","unstructured":"Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TCM (2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma X relapse [intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 15(8):874\u2013885. https:\/\/doi.org\/10.1016\/S1470-2045(14)70245-1","journal-title":"Lancet Oncol"},{"issue":"10","key":"3191_CR58","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M (2010) Melphalan 200 mg\/m2 versus melphalan 100 mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 115(10):1873\u20131879. https:\/\/doi.org\/10.1182\/blood-2009-09-241737","journal-title":"Blood"},{"issue":"16","key":"3191_CR59","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petro D, Evangelista A, Spada S, Pescosta N, Omede P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16(16):1617\u20131629. https:\/\/doi.org\/10.1016\/S1470-2045(15)00389-7","journal-title":"Lancet Oncol"},{"key":"3191_CR60","first-page":"604","volume":"98","author":"E Katodritou","year":"2013","unstructured":"Katodritou E, Anagnostopoulos A, Vadikolia C, Lalayianni C, Kotsopoulou M, Repousis P, Megalakaki A, Rekleiti A, Dadakaridou M, Papageorgiou G, Kyrtsonis M, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michalis E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniati A, Terpos E (2013) \u201cReal world\u201d data from patients with relapsed\/refractory multiple myeloma who have been treated with lenalidomide and dexamethasone, according to the standard clinical practice. Haematologica 98:604","journal-title":"Haematologica"},{"key":"3191_CR61","unstructured":"Celgene (2016) Imnovid (pomalidomide) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002682\/WC500147717.pdf . Accessed 18 Jan 2017"},{"key":"3191_CR62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2014.113217","volume":"100","author":"M Cavo","year":"2015","unstructured":"Cavo M, Dimopoulos MA, Moreau P, Palumbo A, Corradini P, Weisel K, Ocio E, Doyen C, Anttila P, Raymakers R, San Miguel J, Yu X, Milller N, Herring J, Slaughter A, Peluso T, Sternas L, Zaki M, Delforge M (2015) Management of adverse events in the stratus trial, a phase 3b study evaluating safety and efficacy of pomalidomide + low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica 100:253\u2013254","journal-title":"Haematologica"},{"issue":"9","key":"3191_CR63","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","volume":"127","author":"S Zweegman","year":"2016","unstructured":"Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukas E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A (2016) Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 127(9):1109\u20131116. https:\/\/doi.org\/10.1182\/blood-2015-11-679415","journal-title":"Blood"},{"key":"3191_CR64","doi-asserted-by":"publisher","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, Committee EG (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl 4):iv52\u2013iv61. https:\/\/doi.org\/10.1093\/annonc\/mdx096","DOI":"10.1093\/annonc\/mdx096"},{"key":"3191_CR65","unstructured":"Novartis (2016) Farydak (panobinostat) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003725\/WC500193298.pdf . Accessed 18 January 2017"},{"key":"3191_CR66","doi-asserted-by":"publisher","unstructured":"Richardson PG, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, San-Miguel JF (2014) PANORAMA 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 32(15 Suppl 1):8510. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.8510","DOI":"10.1200\/jco.2014.32.15_suppl.8510"},{"key":"3191_CR67","unstructured":"Amgen (2016) Kyprolis (carfilzomib) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003790\/WC500197692.pdf . Accessed 18 January 2017"},{"issue":"17","key":"3191_CR68","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Group T-MS (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"14","key":"3191_CR69","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"issue":"8","key":"3191_CR70","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"issue":"7","key":"3191_CR71","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, KL W, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, Investigators ELOQUENT (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"3191_CR72","first-page":"322","volume":"98","author":"E Muchtar","year":"2013","unstructured":"Muchtar E, Ram R, Raanani P, Yeshurun M, Oniashvili N, Shpliberg O, Magen-Nativ H (2013) Total therapy 3 (TT3)-based treatment for multiple myeloma\u2014an extended single center experience. Haematologica 98:322","journal-title":"Haematologica"},{"key":"3191_CR73","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/j.clml.2015.07.609","volume":"15","author":"I Isola","year":"2015","unstructured":"Isola I, Granell M, Marti JM, Gironella M, Garcia-Guinon A, Lopez-Pardo J, Muntanola A, Abella E, Motllo C, Escoda L, Sierra J, Blade J, Rosinol L, Fernandez De Larrea C (2015) PACE as salvage therapy for relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 15:e300\u2013e301. https:\/\/doi.org\/10.1016\/j.clml.2015.07.609","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3191_CR74","unstructured":"Amgen (2015) Neupogen (filgrastim) summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/23292 . Accessed 12 Sept 2016"},{"key":"3191_CR75","unstructured":"Pharma C (2015) Granocyte (lenograstim) summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/8347 . Accessed 12 Sept 2016"},{"key":"3191_CR76","unstructured":"Amgen (2015) Neulasta (pegfilgrastim) summary of product characteristics. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000420\/human_med_000924.jsp&mid=WC0b01ac058001d124 . Accessed 12 Sept 2016"},{"issue":"2","key":"3191_CR77","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525\u2013545. https:\/\/doi.org\/10.1007\/s00520-014-2457-z","journal-title":"Support Care Cancer"},{"issue":"1","key":"3191_CR78","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11(1):404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"key":"3191_CR79","unstructured":"Sicor Biotech (2016) Lonquex (lipegfilgrastim) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002556\/WC500148380.pdf . Accessed 12 September 2016"},{"issue":"18","key":"3191_CR80","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","volume":"113","author":"S Knop","year":"2009","unstructured":"Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137\u20134143. https:\/\/doi.org\/10.1182\/blood-2008-10-184135","journal-title":"Blood"},{"key":"3191_CR81","doi-asserted-by":"crossref","unstructured":"Scott EC, Vogl DT, Reasor-Heard S, Floyd K, Medvedova E, Spurgeon SE, Gordon M, Kratz A, Siegel MB, Loriaux M, Trubowitz P, Smith SD, Liu SQ, Arora R, Stadtmauer EA, Amaravadi RK, Maziarz RT (2014) A phase I study of hydroxychloroquine with infusional cyclophosphamide, pulse dexamethasone and rapamycin in patients with relapsed or refractory multiple myeloma. Blood 124:3449","DOI":"10.1182\/blood.V124.21.3449.3449"},{"key":"3191_CR82","unstructured":"Radic Kristo D, Zatezalo V, Jaksic B, Acamovic B, Planinc-Peraica A, Ostojic Kolonic S (2014) Comparison of peg-filgrastim versus filgrastim after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 49(Suppl. 1):S456"},{"issue":"2","key":"3191_CR83","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00520-014-2490-y","volume":"23","author":"C Cerchione","year":"2015","unstructured":"Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301\u2013302. https:\/\/doi.org\/10.1007\/s00520-014-2490-y","journal-title":"Support Care Cancer"},{"key":"3191_CR84","doi-asserted-by":"publisher","unstructured":"Tuazon S, Sharma M, Zhan T, Kasner M, Alpdogan O, Martinez U, Grosso D, Filicko J, Pro B, Wagner JL, Carabasi M, Flomenberg N, Weiss M (2014) Autologous stem cell mobilization with pegfilgrastim and planned plerixafor is equally effective and safer as compared with cyclophosphamide, pegfilgrastim and plerixafor. Biol Blood Marrow Transplant 20(Suppl. 2):S119. https:\/\/doi.org\/10.1016\/j.bbmt.2013.12.175","DOI":"10.1016\/j.bbmt.2013.12.175"},{"key":"3191_CR85","unstructured":"Knop S, Langer C, Engelhardt M, Mugge LO, Rosler W, Reichle A, Rollig C, Hertenstein B, Gramatzki M, Bassermann F, Ostermann H, Sturm I, Ringhoffer M, Schafer-Eckart K, Falk K, Liebert A, Einsele H, Bargou R (2013) Lenalidomide, adriamycin, dexamethasone (RAD) followed by risk-adjusted transplant is a novel and very effective induction regimen in newly diagnosed multiple myeloma. Onkologie 36(Suppl. 7):39"},{"key":"3191_CR86","doi-asserted-by":"crossref","unstructured":"Knop S, Langer C, Engelhardt M, Muegge LO, Roesler W, Reichle A, Rollig C, Hertenstein B, Gramatzki M, Bassermann F, Ostermann H, Sturm I, Ringhoffer M, Schaefer-Eckart K, Kraus S, Einsele H, Bargou RC (2013) Lenalidomide, adriamycin and dexamethasone (RAD) as an induction regimen in newly diagnosed multiple myeloma-interim results from a German multicenter phase II trial. Blood 122:1987","DOI":"10.1182\/blood.V122.21.1987.1987"},{"key":"3191_CR87","doi-asserted-by":"crossref","unstructured":"Knop S, Langer C, Engelhardt M, Mugge LO, Reichle A, Rosler W, Bassermann F, Hertenstein B, Sturm I, Rollig C, Ostermann H, Schafer-Eckart K, Ringhoffer M, Gunther A, Junghanss C, Biersack H, Strifler S, Bachinger A, Einsele H, Bargou RC (2014) Response to lenalidomide, doxorubicin and dexamethasone (RAD) in newly diagnosed multiple myeloma is independent of cytogenetic risk and retained after double stem cell transplant. Blood 124:177","DOI":"10.1182\/blood.V124.21.177.177"},{"key":"3191_CR88","doi-asserted-by":"crossref","unstructured":"Costa LJ, Landau H, Venkata JK, Kang Y, Koehne G, Chung DJ, Lendvai N, Bentz T, Giralt S (2013) Phase 1 trial of carfilzomib + high dose melphalan conditioning regimen prior to autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma. Blood 122:3329","DOI":"10.1182\/blood.V122.21.3329.3329"},{"key":"3191_CR89","unstructured":"Carlino D, Mele A, Rossini B, De Francesco R, Sibilla S, Greco G, Fina M, De Risi C, Morciano MR, Ostuni A, Pavone V (2013) Peg filgrastim versus daily granulocyte-colony stimulating factor: a comparison after autologous stem cell transplantation. Single centre experience. Haematologica 98:99"},{"key":"3191_CR90","doi-asserted-by":"publisher","unstructured":"Kroll TM, Singavi A, Schmidt W, Eastwood D, Drobyski W, Horowitz MM, Palmer J, Pasquini MC, Rizzo JD, Saber W, Hari PN, Fenske T (2014) Safety of outpatient autologous hematopoietic cell transplantation (AUHCT) for multiple myeloma and lymphoma. Biol Blood Marrow Transplant 20(2 Suppl.):S114. https:\/\/doi.org\/10.1016\/j.bbmt.2013.12.166","DOI":"10.1016\/j.bbmt.2013.12.166"},{"issue":"3","key":"3191_CR91","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2012.145","volume":"48","author":"KE Herbert","year":"2013","unstructured":"Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM (2013) Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 48(3):351\u2013356. https:\/\/doi.org\/10.1038\/bmt.2012.145","journal-title":"Bone Marrow Transplant"},{"key":"3191_CR92","doi-asserted-by":"publisher","unstructured":"Herrera JM, Huertas JF, Saavedra MA, Gomez R, Guerrero AJ, Duque JE, Urrego OM, Del Pilar Salcedo R, Martinez A (2014) Pegylated filgrastim is comparable with filgrastim as support for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20(2 Suppl.):S112. https:\/\/doi.org\/10.1016\/j.bbmt.2013.12.161","DOI":"10.1016\/j.bbmt.2013.12.161"},{"key":"3191_CR93","unstructured":"Aspen Pharma (2014) Summary of product characteristics: melphalan 50 mg powder and solvent for solution for injection\/infusion. https:\/\/www.medicines.org.uk\/emc\/medicine\/703 . Accessed 16 October 2016"},{"issue":"11","key":"3191_CR94","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm1101-1209","volume":"7","author":"S Partida-Sanchez","year":"2001","unstructured":"Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmsen A, Randall TD, Lund FE (2001) Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7(11):1209\u20131216. https:\/\/doi.org\/10.1038\/nm1101-1209","journal-title":"Nat Med"},{"key":"3191_CR95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-370607-2.00002-8","volume-title":"Hematopathology","author":"F Naeim","year":"2008","unstructured":"Naeim F (2008) Chapter 2\u2014principles of immunophenotyping. In: Hematopathology, pp 27\u201355. https:\/\/doi.org\/10.1016\/B978-0-12-370607-2.00002-8"},{"issue":"2","key":"3191_CR96","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","volume":"47","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Tay K, Wilson WH (2010) Rituximab-associated neutropenia. Semin Hematol 47(2):180\u2013186. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.009","journal-title":"Semin Hematol"},{"issue":"2","key":"3191_CR97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.critrevonc.2011.03.003","volume":"81","author":"A Chan","year":"2012","unstructured":"Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T (2012) Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol 81(2):136\u2013150. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.003","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3191-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T23:01:39Z","timestamp":1603580499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3191-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3191"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3191-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}